Johnson & Johnson (NYSE:JNJ) Shares Sold by Insight 2811 Inc.

Insight 2811 Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 1.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,402 shares of the company’s stock after selling 68 shares during the quarter. Johnson & Johnson accounts for 0.4% of Insight 2811 Inc.’s investment portfolio, making the stock its 26th biggest position. Insight 2811 Inc.’s holdings in Johnson & Johnson were worth $855,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $4,071,642,000. Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 16.4% during the fourth quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock worth $3,764,852,000 after purchasing an additional 3,391,657 shares in the last quarter. International Assets Investment Management LLC lifted its stake in shares of Johnson & Johnson by 7,875.8% during the fourth quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock worth $327,647,000 after purchasing an additional 2,064,175 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $193,050,000. Finally, Focused Investors Fund L P acquired a new position in shares of Johnson & Johnson in the first quarter worth about $193,996,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Bank of America dropped their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, July 1st. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a report on Monday, June 17th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. Finally, Morgan Stanley reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.07.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $149.88 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The firm’s 50-day moving average price is $147.94 and its two-hundred day moving average price is $153.48. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The stock has a market capitalization of $360.71 billion, a P/E ratio of 9.34, a P/E/G ratio of 2.50 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter last year, the company posted $2.68 earnings per share. Johnson & Johnson’s revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were paid a $1.24 dividend. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.31%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.